Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study

Author:

Ruhen Olivia1ORCID,Lak Nathalie S.M.23ORCID,Stutterheim Janine23ORCID,Danielli Sara G.4ORCID,Chicard Mathieu5,Iddir Yasmine5ORCID,Saint-Charles Alexandra5,Di Paolo Virginia6ORCID,Tombolan Lucia7,Gatz Susanne A.18ORCID,Aladowicz Ewa1,Proszek Paula19,Jamal Sabri19,Stankunaite Reda1910ORCID,Hughes Deborah19,Carter Paul19,Izquierdo Elisa19ORCID,Wasti Ajla11ORCID,Chisholm Julia C.1112ORCID,George Sally L.111,Pace Erika1113ORCID,Chesler Louis111ORCID,Aerts Isabelle5,Pierron Gaelle5ORCID,Zaidi Sakina14ORCID,Delattre Olivier14,Surdez Didier1415ORCID,Kelsey Anna16,Hubank Michael19ORCID,Bonvini Paolo7,Bisogno Gianni17ORCID,Di Giannatale Angela6,Schleiermacher Gudrun518ORCID,Schäfer Beat W.4,Tytgat Godelieve A.M.23,Shipley Janet1

Affiliation:

1. Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom

2. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands

3. Experimental Immunohematology, Sanquin, Amsterdam, the Netherlands

4. Department of Oncology and Children's Research Centre, University Children's Hospital, Zurich, Switzerland

5. SiRIC RTOP (Recherche Translationelle en Oncologie Pediatrique), Institut Curie, Paris, France

6. Department of Pediatric Haematology/Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

7. Institute of Pediatric Research, Fondazione Città della Speranza, Padova, Italy

8. Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom

9. Molecular Diagnostics, Royal Marsden NHS Foundation Trust, London, United Kingdom

10. Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom

11. Children & Young People's Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom

12. Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom

13. Department of Diagnostic Radiology, Royal Marsden NHS Foundation Trust, London, United Kingdom

14. INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, Paris, France

15. Bone Sarcoma Research Laboratory, Balgrist University Hospital, University of Zurich, Zurich, Switzerland

16. Department of Pediatric Histopathology, Manchester University Foundation Trust, Manchester, United Kingdom

17. Department of Woman's and Children's Health, Hematology and Oncology Unit, University of Padova, Padova, Italy

18. Department of Pediatric Oncology, Hospital Group, Institut Curie, Paris, France

Abstract

PURPOSE Rhabdomyosarcomas (RMS) are rare neoplasms affecting children and young adults. Efforts to improve patient survival have been undermined by a lack of suitable disease markers. Plasma circulating tumor DNA (ctDNA) has shown promise as a potential minimally invasive biomarker and monitoring tool in other cancers; however, it remains underexplored in RMS. We aimed to determine the feasibility of identifying and quantifying ctDNA in plasma as a marker of disease burden and/or treatment response using blood samples from RMS mouse models and patients. METHODS We established mouse models of RMS and applied quantitative polymerase chain reaction (PCR) and droplet digital PCR (ddPCR) to detect ctDNA within the mouse plasma. Potential driver mutations, copy-number alterations, and DNA breakpoints associated with PAX3/ 7-FOXO1 gene fusions were identified in the RMS samples collected at diagnosis. Patient-matched plasma samples collected from 28 patients with RMS before, during, and after treatment were analyzed for the presence of ctDNA via ddPCR, panel sequencing, and/or whole-exome sequencing. RESULTS Human tumor-derived DNA was detectable in plasma samples from mouse models of RMS and correlated with tumor burden. In patients, ctDNA was detected in 14/18 pretreatment plasma samples with ddPCR and 7/7 cases assessed by sequencing. Levels of ctDNA at diagnosis were significantly higher in patients with unfavorable tumor sites, positive nodal status, and metastasis. In patients with serial plasma samples (n = 18), fluctuations in ctDNA levels corresponded to treatment response. CONCLUSION Comprehensive ctDNA analysis combining high sensitivity and throughput can identify key molecular drivers in RMS models and patients, suggesting potential as a minimally invasive biomarker. Preclinical assessment of treatments using mouse models and further patient testing through prospective clinical trials are now warranted.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3